Abstract
Background: Traditionally bronchodilator reversibility is observed with sort acting β2 agonist as salbutamol and not with any antimuscarinic agent (AMA) for COPD. Since glycopyrronium (GP), quick onset AMA, has optimal bronchodilatory effect by 30 minutes, it may be tested for reversibility assessment.
Objective: To compare bronchodilator response in GP and salbutamol
Method: On ethical approval, consecutive patients of historically and clinically diagnosed COPD were included for either GP (50 µg single dose dry powder inhaler) or levo-salbutamol (4 puffs of 50 µg each) for reversibility. The patients with similar lung functions (post bronchodilator FEV1/FVC and FEV1) in each category were compared statistically.
Results: 70 and 88 patients of GP and salbutamol reversibility were included in a period of 78 days. The two groups had similar demographic and lung function status. The change in FEV1 was significantly high in GP group than salbutamol (105 ml vs. 61 ml; p=0.02). When divided according to GOLD staging, the changes in GOLD 1 and GOLD 3 were significantly better for GP (n=23 and 18 for GP and n=35 and 15 for salbutamol, for GOLD 1 and GOLD 3 respectively). The GOLD 2 and GOLD 4 cases also showed a similar trend although not statistically significant.
Conclusions: Testing reversibility with GP appears feasible in clinical practice and the GP reversibility appears to be better than salbutamol. Further research is needed to establish the role of GP reversibility in clinical practice.
Footnotes
Cite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA2480.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2019